Caroline Krogh Søgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Caroline Krogh Søgaard has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Marit Otterlei
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU)
4 shared publications - Per Bruheim
Department of Biotechnology and Food Science, NTNU Norwegian University of Science and Technology, Trondheim, Norway
2 shared publications - Animesh Sharma
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
1 shared publication - Bård Helge Hoff
Department of Chemistry, Norwegian University of Science and Technology (NTNU), Høgskoleringen 5, NO-7491 Trondheim, Norway
1 shared publication - Camilla Olaisen
Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
1 shared publication Carl-Jørgen Arum
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Urology and Surgery, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
1 shared publication
Latest Publications
- 14 May 2024
- Published by Elsevier
- Vol. 100, 209-246
Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy
- 14 May 2024
- Published by Elsevier
- Vol. 100, 209-246
Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy
- Open Access
- 23 December 2022
- Published by Springer Nature in Oncogene
- Vol. 42 (8) , 613-624
PCNA regulates primary metabolism by scaffolding metabolic enzymes
The essential roles of proliferating cell nuclear antigen (PCNA) as a scaffold protein in DNA replication and repair are well established, while its cytosolic roles are less explored. Two metabolic enzymes, alpha-enolase (ENO1) and 6-phosphogluconate dehydrogenase (6PGD), both contain PCNA interacting motifs. Mutation of the PCNA interacting motif APIM in ENO1 (F423A) impaired its binding to PCNA and resulted in reduced cellular levels of ENO1 protein, reduced growth rate, reduced glucose consumption, and reduced activation of AKT. Metabolome and signalome analysis reveal large consequences of impairing the direct interaction between PCNA and ENO1. Metabolites above ENO1 in glycolysis accumulated while lower glycolytic and TCA cycle metabolite pools decreased in the APIM-mutated cells; however, their overall energetic status were similar to parental cells. Treating haematological cancer cells or activated primary monocytes with a PCNA targeting peptide drug containing APIM (ATX-101) also lead to a metabolic shift characterized by reduced glycolytic rate. In addition, we show that ATX-101 treatments reduced the ENO1 - PCNA interaction, the ENO1, GAPDH and 6PGD protein levels, as well as the 6PGD activity. Here we report for the first time that PCNA acts as a scaffold for metabolic enzymes, and thereby act as a direct regulator of primary metabolism.
- 23 December 2022
- Published by Springer Nature in Oncogene
- Vol. 42 (8) , 613-624
Open AccessPCNA regulates primary metabolism by scaffolding metabolic enzymes
The essential roles of proliferating cell nuclear antigen (PCNA) as a scaffold protein in DNA replication and repair are well established, while its cytosolic roles are less explored. Two metabolic enzymes, alpha-enolase (ENO1) and 6-phosphogluconate dehydrogenase (6PGD), both contain PCNA interacting motifs. Mutation of the PCNA interacting motif APIM in ENO1 (F423A) impaired its binding to PCNA and resulted in reduced cellular levels of ENO1 protein, reduced growth rate, reduced glucose consumption, and reduced activation of AKT. Metabolome and signalome analysis reveal large consequences of impairing the direct interaction between PCNA and ENO1. Metabolites above ENO1 in glycolysis accumulated while lower glycolytic and TCA cycle metabolite pools decreased in the APIM-mutated cells; however, their overall energetic status were similar to parental cells. Treating haematological cancer cells or activated primary monocytes with a PCNA targeting peptide drug containing APIM (ATX-101) also lead to a metabolic shift characterized by reduced glycolytic rate. In addition, we show that ATX-101 treatments reduced the ENO1 - PCNA interaction, the ENO1, GAPDH and 6PGD protein levels, as well as the 6PGD activity. Here we report for the first time that PCNA acts as a scaffold for metabolic enzymes, and thereby act as a direct regulator of primary metabolism.
- Open Access
- 13 April 2021
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2021 (18) , 2701-2712
Synthetic Strategies towards Imidazopyridinones and 7‐Azaoxindoles and their Evaluation as Antibacterial Agents
Imidazopyridinones and 7‐azaoxindoles are two classes of heterocyclic compounds with only limited previous use in organic and medicinal chemistry. Various synthetic methods and routes have been evaluated to identify safe and robust chemistry to advanced imidazopyridinone building blocks and inhibitor structures. Preparation of the 7‐azaoxindoles was challenged by instability of the core scaffold. Key to the successful isolation of the target structure was development of a mild Suzuki cross‐coupling in non‐aqueous media. The imidazopyridinones were potent inhibitors of the E. coli thymidylate monophosphate kinase, while the 7‐azaoxindole showed low activity. The compounds were inactive in cell‐based studies, indicating poor cell wall penetration.
- 13 April 2021
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2021 (18) , 2701-2712
Open AccessSynthetic Strategies towards Imidazopyridinones and 7‐Azaoxindoles and their Evaluation as Antibacterial Agents
Imidazopyridinones and 7‐azaoxindoles are two classes of heterocyclic compounds with only limited previous use in organic and medicinal chemistry. Various synthetic methods and routes have been evaluated to identify safe and robust chemistry to advanced imidazopyridinone building blocks and inhibitor structures. Preparation of the 7‐azaoxindoles was challenged by instability of the core scaffold. Key to the successful isolation of the target structure was development of a mild Suzuki cross‐coupling in non‐aqueous media. The imidazopyridinones were potent inhibitors of the E. coli thymidylate monophosphate kinase, while the 7‐azaoxindole showed low activity. The compounds were inactive in cell‐based studies, indicating poor cell wall penetration.
- Open Access
- 1 December 2014
- Published by Elsevier in Translational Oncology
- Vol. 7 (6) , 812-823
Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide
- 1 December 2014
- Published by Elsevier in Translational Oncology
- Vol. 7 (6) , 812-823
Open AccessIncreased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide